Vontobel Holding Ltd. Invests $400,000 in Charles River Laboratories International, Inc. (NYSE:CRL)

Vontobel Holding Ltd. purchased a new position in Charles River Laboratories International, Inc. (NYSE:CRL) during the fourth quarter, Holdings Channel.com reports. The firm purchased 1,691 shares of the medical research company’s stock, valued at approximately $400,000.

Other large investors have also recently bought and sold shares of the company. Regency Capital Management Inc. DE bought a new stake in Charles River Laboratories International in the fourth quarter worth $3,703,000. WCM Investment Management LLC bought a new stake in Charles River Laboratories International in the fourth quarter worth $1,396,000. DekaBank Deutsche Girozentrale boosted its holdings in Charles River Laboratories International by 98.6% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 14,094 shares of the medical research company’s stock worth $3,333,000 after purchasing an additional 6,997 shares in the last quarter. AMG National Trust Bank bought a new stake in Charles River Laboratories International in the third quarter worth $1,119,000. Finally, DAVENPORT & Co LLC bought a new stake in Charles River Laboratories International in the fourth quarter worth $1,904,000. 98.91% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Shannon M. Parisotto sold 5,882 shares of the firm’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the completion of the transaction, the executive vice president now owns 2,596 shares in the company, valued at $626,155.20. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Charles River Laboratories International news, EVP Victoria L. Creamer sold 5,000 shares of the firm’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $253.70, for a total transaction of $1,268,500.00. Following the completion of the transaction, the executive vice president now owns 13,550 shares in the company, valued at $3,437,635. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Shannon M. Parisotto sold 5,882 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the completion of the transaction, the executive vice president now owns 2,596 shares of the company’s stock, valued at approximately $626,155.20. The disclosure for this sale can be found here. Insiders sold a total of 14,932 shares of company stock worth $3,693,663 over the last quarter. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International Stock Up 3.2 %

CRL stock opened at $239.98 on Wednesday. Charles River Laboratories International, Inc. has a twelve month low of $161.65 and a twelve month high of $275.00. The company has a market cap of $12.36 billion, a PE ratio of 26.06, a price-to-earnings-growth ratio of 1.78 and a beta of 1.40. The business’s 50-day simple moving average is $254.27 and its 200 day simple moving average is $222.23. The company has a quick ratio of 1.16, a current ratio of 1.52 and a debt-to-equity ratio of 0.73.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, February 14th. The medical research company reported $2.46 earnings per share for the quarter, topping analysts’ consensus estimates of $2.39 by $0.07. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $991.25 million. Charles River Laboratories International had a return on equity of 16.53% and a net margin of 11.49%. The firm’s revenue for the quarter was down 7.9% compared to the same quarter last year. During the same period last year, the business earned $2.98 earnings per share. On average, research analysts anticipate that Charles River Laboratories International, Inc. will post 11.01 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have issued reports on CRL. Argus upped their price target on shares of Charles River Laboratories International from $240.00 to $290.00 and gave the company a “buy” rating in a report on Monday, March 18th. Citigroup upped their price target on shares of Charles River Laboratories International from $215.00 to $250.00 and gave the company a “neutral” rating in a report on Thursday, February 15th. UBS Group upped their price target on shares of Charles River Laboratories International from $270.00 to $290.00 and gave the company a “buy” rating in a report on Thursday, February 15th. JPMorgan Chase & Co. upped their price target on shares of Charles River Laboratories International from $270.00 to $280.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. Finally, Robert W. Baird upped their price target on shares of Charles River Laboratories International from $252.00 to $268.00 and gave the company an “outperform” rating in a report on Thursday, February 15th. Five research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Charles River Laboratories International presently has an average rating of “Moderate Buy” and an average target price of $253.23.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).